602 related articles for article (PubMed ID: 25582080)
1. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
2. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
3. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
4. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
5. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
7. Effect of cytotoxic T-lymphocyte-associated protein 4 on CD4(+)CD25(+) regulatory T cells in murine schistosomiasis japonica.
Tang CL; Lei JH; Guan F; Li YL; Liu R; Grevelding CG; Jiang MS; Dong HF
Exp Parasitol; 2014 Jan; 136():74-8. PubMed ID: 24269199
[TBL] [Abstract][Full Text] [Related]
8. Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells.
Cong L; Wang SF; Zhao ZL; Yang RY
Transplantation; 2016 Apr; 100(4):763-71. PubMed ID: 26569069
[TBL] [Abstract][Full Text] [Related]
9. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
[TBL] [Abstract][Full Text] [Related]
10. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
[TBL] [Abstract][Full Text] [Related]
12. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
13. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Peggs KS; Quezada SA; Chambers CA; Korman AJ; Allison JP
J Exp Med; 2009 Aug; 206(8):1717-25. PubMed ID: 19581407
[TBL] [Abstract][Full Text] [Related]
14. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cells.
Wang B; Li B; Dai Z; Ren S; Bai M; Wang Z; Li Z; Lin S; Wang Z; Huang N; Yang P; Liu M; Min W; Ma H
Int J Biochem Cell Biol; 2014 Oct; 55():98-108. PubMed ID: 25168696
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
16. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Mitchell DA; Cui X; Schmittling RJ; Sanchez-Perez L; Snyder DJ; Congdon KL; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Blood; 2011 Sep; 118(11):3003-12. PubMed ID: 21768296
[TBL] [Abstract][Full Text] [Related]
18. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
19. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
20. IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.
Müller M; Herrath J; Malmström V
Clin Exp Immunol; 2015 Oct; 182(1):90-100. PubMed ID: 26076982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
